Heterogeneous Hippo pathway (YAP/TAZ) activation in lung adenocarcinoma drives tumor progression by enabling ferroptosis ...

The activity of erlotinib in advanced NSCLC patients with EGFR mutations was first evaluated in a large Spanish trial, where lung cancers from 2105 patients were screened for EGFR mutations. [23] ...

After adjustment, independent predictors of acute eGFR dip with empagliflozin included: Older age: -0.9% difference in acute eGFR change per 10-year increase in age (95% CI -1.1 to -0.6) ...